首页> 美国卫生研究院文献>PLoS Medicine >CD47 Agonist Peptides Induce Programmed Cell Death in Refractory Chronic Lymphocytic Leukemia B Cells via PLCγ1 Activation: Evidence from Mice and Humans
【2h】

CD47 Agonist Peptides Induce Programmed Cell Death in Refractory Chronic Lymphocytic Leukemia B Cells via PLCγ1 Activation: Evidence from Mice and Humans

机译:CD47激动剂肽通过PLCγ1激活导致难治性慢性淋巴细胞性白血病B细胞程序性死亡:来自小鼠和人类的证据

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundChronic lymphocytic leukemia (CLL), the most common adulthood leukemia, is characterized by the accumulation of abnormal CD5+ B lymphocytes, which results in a progressive failure of the immune system. Despite intense research efforts, drug resistance remains a major cause of treatment failure in CLL, particularly in patients with dysfunctional TP53. The objective of our work was to identify potential approaches that might overcome CLL drug refractoriness by examining the pro-apoptotic potential of targeting the cell surface receptor CD47 with serum-stable agonist peptides.
机译:背景慢性淋巴细胞性白血病(CLL)是成年期最常见的白血病,其特征在于异常CD5 + B淋巴细胞蓄积,导致免疫系统进行性衰竭。尽管进行了大量的研究,但耐药性仍然是CLL治疗失败的主要原因,特别是在TP53功能异常的患者中。我们工作的目的是通过检查血清稳定的激动剂肽靶向细胞表面受体CD47的促凋亡潜力,从而确定可能克服CLL难治性的潜在方法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号